Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Cancer Investigation
|
September 20, 2006
Targeted therapy for renal cell carcinoma: a new therapeutic paradigm
Philip E Shaheen, Ronald M Bukowski
Expert Opinion on Emerging Drugs
|
November 3, 2005
Emerging drugs for renal cell carcinoma
Philip E Shaheen, Ronald M Bukowski
Clinical Genitourinary Cancer
|
July 25, 2006
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports
Philip E Shaheen, Brian I Rini, Ronald M Bukowski
Clinical Orthopaedics and Related Research
|
April 20, 2002
Extensor hallucis longus innervation: an anatomic study
Hossein Elgafy, Nabil A Ebraheim, Philip E Shaheen, et al.
Journal of Pain and Symptom Management
|
September 9, 2009
Opioid equianalgesic tables: are they all equally dangerous?
Philip E Shaheen, Declan Walsh, Wael Lasheen, et al.
Investigational New Drugs
|
July 22, 2005
Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma
Philip E Shaheen, Walter Stadler, Paul Elson, et al.
The American Journal of Hospice & Palliative Care
|
July 3, 2007
The business of palliative medicine - part 5: service utilization in a comprehensive integrated program
Bassam Estfan, Mellar P Davis, Declan Walsh, et al.
Journal of Pain and Symptom Management
|
April 24, 2010
Errors in opioid prescribing: a prospective survey in cancer pain
Philip E Shaheen, Susan B Legrand, Declan Walsh, et al.
Cancer
|
September 20, 2006
Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma
Revathi Suppiah, Philip E Shaheen, Paul Elson, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Cancer Investigation
|
September 20, 2006
Targeted therapy for renal cell carcinoma: a new therapeutic paradigm
Philip E Shaheen, Ronald M Bukowski
Expert Opinion on Emerging Drugs
|
November 3, 2005
Emerging drugs for renal cell carcinoma
Philip E Shaheen, Ronald M Bukowski
Clinical Genitourinary Cancer
|
July 25, 2006
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports
Philip E Shaheen, Brian I Rini, Ronald M Bukowski
Clinical Orthopaedics and Related Research
|
April 20, 2002
Extensor hallucis longus innervation: an anatomic study
Hossein Elgafy, Nabil A Ebraheim, Philip E Shaheen, et al.
Journal of Pain and Symptom Management
|
September 9, 2009
Opioid equianalgesic tables: are they all equally dangerous?
Philip E Shaheen, Declan Walsh, Wael Lasheen, et al.
Investigational New Drugs
|
July 22, 2005
Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma
Philip E Shaheen, Walter Stadler, Paul Elson, et al.
The American Journal of Hospice & Palliative Care
|
July 3, 2007
The business of palliative medicine - part 5: service utilization in a comprehensive integrated program
Bassam Estfan, Mellar P Davis, Declan Walsh, et al.
Journal of Pain and Symptom Management
|
April 24, 2010
Errors in opioid prescribing: a prospective survey in cancer pain
Philip E Shaheen, Susan B Legrand, Declan Walsh, et al.
Cancer
|
September 20, 2006
Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma
Revathi Suppiah, Philip E Shaheen, Paul Elson, et al.
Page
of 1